cd40

Teneliximab (Chi220) is a chimeric monoclonal antibody and a tumor necrosis factor receptor superfamily member 5 (CD40) inhibitor that blocks CD40-CD40L interactions.Teneliximab exerts partial agonist activity through CD40 and peripheral B-cell depletion, and may be used to study organ transplant rejection and rheumatoid arthritis.

Cifurtilimab (SEA-CD40), a nonfucosylated humanized IgG1 monoclonal antibody with agonistic properties, targets the CD40 receptor and demonstrates antitumor activities [1] [2].

Bleselumab (ASKP 1240), a human anti-CD40 monoclonal antibody (mAb), exhibits high-affinity binding to CD40 (Kd: 0.24 nM) and hinders immune responses by impeding the CD40-CD40L interaction, thereby preventing organ transplant rejection [1].

Sotigalimab, a CD40 agonistic monoclonal antibody, is used in research targeting metastatic pancreatic adenocarcinoma [1].

Mitazalimab (ADC-1013; JNJ-64457107) is an FcγR-dependent CD40 agonist that targets tumors by activating antigen-presenting cells like dendritic cells (DC), initiating tumor-reactive T cells, promoting tumor-specific T cell infiltration and destruction of tumors, and remodeling the tumor-infiltrating myeloid microenvironment [1] [2].

Omalizumab is a recombinant humanized monoclonal antibody against human immunoglobulin E IgE)

Lucatumumab (HCD122), a fully human anti-CD40 antagonist monoclonal antibody, effectively inhibits CD40/CD40L-mediated signaling and promotes antibody-dependent cell-mediated cytotoxicity (ADCC) for tumor cell clearance. It is applicable in refractory lymphomas, CLL, and multiple myeloma research [1] [2].

Inezetamab is a bispecific anti-CD40 and anti-MSLN IgG1 monoclonal antibody [1].

Tecaginlimab (BNT-312), an Fc-inert bispecific antibody, is designed for the dual targeting and conditional activation of CD40 and 4-1BB, aiming to improve the priming and reactivation of tumor-specific immunity [1].

Dalnicastobart (LVGN-7409) is a human IgG1κ monoclonal antibody that specifically targets CD40, also known as TNFRSF5 [1].

Dacetuzumab (SGN-40), a humanized IgG1 anti-CD40 monoclonal antibody, exhibits anti-lymphoma activity by inducing tumor cell death through immune effector functions (antibody-dependent cellular cytotoxicity and phagocytosis [ADCC/ADCP]). It is utilized in research on multiple myeloma [1].

Iscalimab (CFZ-533), a non-depleting IgG1 monoclonal antibody that targets CD40 with a dissociation constant (K D) of 0.3 nM, is utilized in the research of Graves' hyperthyroidism and autoimmune diseases [1] [2] [3].

Tegoprubart is a monoclonal antibody targeting CD40 ligand (CD40L), which plays a critical role in costimulation. By inhibiting CD40L, it diminishes both cellular and antibody-mediated immune responses, fostering a more tolerant immune milieu. The efficacy of Tegoprubart has been confirmed in vivo within transplantation animal models.

Selicrelumab, an agonist CD40 antibody, modifies the tumor microenvironment and is utilized in pancreatic cancer research and neoadjuvant studies [1].

Toralizumab (IDEC-131), a humanized monoclonal antibody (mAb) directed against CD40L (CD154), consists of human gamma 1 heavy chains and human kappa light chains. Specifically targeting CD40L on T cells, it inhibits CD40 signaling, acting as an immunosuppressive agent with potential applications in systemic lupus erythematosus (SLE) research [1] [2].

Frexalimab (SAR441344; INX-021), a monoclonal antibody that targets the CD40 ligand (CD40L), shows promise for research in multiple sclerosis [1].

Ravagalimab (ABBV-323), a CD40 antagonist with an EC50 of 3.7 nM, is utilized in the research of Crohn's disease [1].

Giloralimab (ABBV-927), an agonistic monoclonal antibody targeting CD40, exhibits potent activity and is being investigated for potential application in cancer research [1] [2].